Answers are grounded in this paper and cite their sources.
Expert consensus reveals clinical recommendations for peripheral T-cell lymphoma in Latin America, highlighting standardized staging and resource-adapted treatment protocols.
PURPOSE Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is an aggressive, heterogeneous subtype of non-Hodgkin lymphoma with poor prognosis and limited therapeutic options. In Latin America (LATAM), management is challenged by restricted access to advanced diagnostics, higher prevalence of oncogenic viruses (Epstein-Barr virus, HTLV-1), and variable health care resources. This international consensus provides evidence-based, regionally adapted recommendations for diagnosis, staging, risk stratification, treatment, and follow-up of adult patients with PTCL-NOS. METHODS A multidisciplinary panel of hematologists and oncologists from multiple LATAM countries, who are members of the Grupo de Estudio Latinoamericano de Linfoproliferativos , used a modified Delphi process (February-July 2025). An initial questionnaire of 11 items addressed diagnostic evaluation, staging, risk stratification, first-line therapy, response assessment, consolidation with stem-cell transplantation, salvage therapy, and supportive care. Consensus was defined as ≥80% agreement on a five-point Likert scale using the RAND/UCLA appropriateness method. Two rounds of anonymous voting and discussion incorporated cost-effectiveness and local resource constraints. RESULTS Key recommendations include (1) positron emission tomography (PET)/computed tomography (CT) as preferred staging modality (with total metabolic tumor volume for prognostication) plus mandatory bone-marrow biopsy; (2) Prognostic Index for PTCL-U as primary risk-stratification tool; (3) cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone for fit patients ≤60 years with planned autologous stem-cell transplantation (ASCT), versus cyclophosphamide, doxorubicin, vincristine, and prednisone-21 otherwise; (4) brentuximab vedotin + cyclophosphamide, doxorubicin, prednisone for CD30 + cases (≥10% expression); (5) interim and end-of-treatment PET/CT for response assessment; (6) ASCT in first complete remission; (7) early allogeneic transplantation referral for relapsed/refractory disease; and (8) standardized immunohistochemistry/flow cytometry panels. Resource-limited adaptations prioritize accessible strategies and encourage clinical trial participation. CONCLUSION This LATAM-specific consensus integrates global evidence with regional realities to optimize outcomes for PTCL-NOS. Implementation should standardize care, reduce diagnostic delays, and improve equitable access to effective therapies across LATAM.
No takes yet. Share an insight, caveat, or question.
Idrobo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: